NPCE

Insider Trades

Name	Value	Action	Price	Current Price
Morrell MarthaCHIEF MEDICAL OFFICER $399k25k shares SellDec 15, 2025 $15.97 --
Orbimed Advisors LLC10 Percent Owner $2.1M134.1k shares SellMay 14, 2025 $15.83 --
Orbimed Advisors LLC10 Percent Owner $542k34k shares SellMay 14, 2025 $15.94 --

News

zacks.comNPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsyzacks.comJun 2

businesswire.comNeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meetingbusinesswire.comMay 29

businesswire.comNeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Carebusinesswire.comMay 29

zacks.comIs NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?zacks.comMay 27

zacks.comNPCE Explains How NeuroPace's RNS System Makes Moneyzacks.comMay 27

Trade NPCE

About NeuroPace, Inc.

NeuroPace, Inc. is a U.S.-based medical technology firm. It specializes in the creation and distribution of the RNS system, an advanced brain-responsive neuromodulation device designed to manage medically intractable focal epilepsy. This innovative system delivers tailored, real-time therapy directly to the source of seizures. Furthermore, the RNS system continuously records brain activity, providing medical professionals with the capability to monitor patients both on-site and remotely. The company supplies its devices to hospitals for both initial surgical implantations and subsequent replacement procedures. NeuroPace, Inc. was founded in 1997 and maintains its corporate headquarters in Mountain View, California.

CEO: Joel D. Becker
IPO Date: Apr 22, 2021

Market Data

Open: $15.70
High: $16.20
Low: $15.47
Volume: 94.6K
52W High: $19.60
52W Low: $7.56

Valuation

Market Cap: $544M
Enterprise Value: $600M

Financials

Free Cash Flow: $-11M
Revenue: $100M
Net Income: $-21M
Cash: $22M
Debt: $71M

Events

EarningsAug 11

EPS est. -0.19